Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Yanling Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6387-8561; OpenAlex author ID A5100629229. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 8

  1. Comprehensive analysis of the expression and prognostic value of ARMCs in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-024-13365-5↗
  2. Targeting the MCP-GPX4/HMGB1 Axis for Effectively Triggering Immunogenic Ferroptosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202308208↗
  3. BCL2A1 neoepitope-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer. Last author DOI 10.1093/jleuko/qiae092↗
  4. Construction and Validation of an Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Based on Public Databases. Co-author DOI 10.3389/fgene.2021.702102↗
  5. Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer… Co-author DOI 10.3389/fonc.2021.646082↗
  6. Silencing of long noncoding RNA LINC00958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8. Co-author DOI 10.1016/j.canlet.2018.12.017↗
  7. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: … Co-author DOI 10.1016/j.ijbiomac.2017.03.123↗
  8. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2126↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shi Chen · 5 shared papers, 2014–2025 · strength 0.65
  2. Yifeng Tian · 4 shared papers, 2017–2024 · strength 0.47
  3. Zuwei Wang · 2 shared papers, 2024–2025 · strength 0.41
  4. Huixing Chen · 3 shared papers, 2017–2025 · strength 0.39
  5. Cheng‐Yu Liao · 2 shared papers, 2021–2024 · strength 0.31
  6. Guanxiang Zhuo · 1 shared paper, 2025 · strength 0.23
  7. Jiangzhi Chen · 2 shared papers, 2014–2024 · strength 0.23
  8. Jingwen Hong · 1 shared paper, 2024 · strength 0.22
  9. Yunbin Ye · 1 shared paper, 2024 · strength 0.22
  10. Shengzhe Lin · 1 shared paper, 2024 · strength 0.22
  11. Chenghong Peng · 3 shared papers, 2014–2019 · strength 0.20
  12. Shun‐Cang Zhu · 1 shared paper, 2024 · strength 0.18
  13. Ge Li · 1 shared paper, 2024 · strength 0.18
  14. Qian Zhan · 2 shared papers, 2014–2021 · strength 0.16
  15. Yao-Dong Wang · 2 shared papers, 2017–2019 · strength 0.16
  16. Miaobin Mao · 1 shared paper, 2021 · strength 0.16
  17. Benhua Xu · 1 shared paper, 2021 · strength 0.16
  18. Rong Zheng · 1 shared paper, 2021 · strength 0.16
  19. Baiyong Shen · 2 shared papers, 2014–2019 · strength 0.13
  20. Can Yang · 1 shared paper, 2021 · strength 0.12
  21. Ge Li · 1 shared paper, 2021 · strength 0.12
  22. Yi Zhu · 1 shared paper, 2014 · strength 0.04
  23. Zhaoyuan Hou · 1 shared paper, 2014 · strength 0.04
  24. Xiaxing Deng · 1 shared paper, 2014 · strength 0.04
  25. Hao Chen · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.